P059 RACIAL VARIATION IN MYELOSUPPRESSION HOSPITALIZATIONS AMONG INFLAMMATORY BOWEL DISEASE PATIENTS. (7th February 2019)

• Record Type: Journal Article
• Authors: Suk, Ryan; Deshmukh, Ashish A; Sonawane, Kalyani B; Song, Jihee; Huo, Jinhai
• Is Part Of: Inflammatory bowel diseases. Volume 25(2019)Supplement 1
• Page Start: S28
• Page End: S28
• Publication Date: 2019-02-07
• Subjects: Inflammatory bowel diseases -- Periodicals; Colitis, Ulcerative -- Periodicals; Crohn Disease -- Periodicals; Inflammatory Bowel Diseases -- Periodicals; 616.344
• DOI: 10.1093/ibd/izy393.065
• Languages: English
• ISSNs: 1078-0998

Abstract

Abstract: Background: Thiopurine therapy is used as a standard of care in inflammatory bowel disease (IBD), but it might cause fatal myelosuppressive adverse events that require hospitalization. To reduce the risk of myelosuppression hospitalizations, a systematic clinical assessment of patients while on thiopurine therapy is needed. While racial disparities in IBD treatment and management has been well-documented in the US, whether these racial disparities have caused high risk of myelosuppression hospitalizations in minority population is still unknown. Methods: We used the Nationwide Inpatient Sample (NIS) from 2003 to 2014 to identify patients who were hospitalized with a primary diagnosis of IBD, or IBD-related complications. Our primary outcome measure was the prevalence of hospitalizations from myelosuppressive adverse events (neutropenia/leukopenia, drug-induced anemia, or thrombocytopenia) among these IBD patients. We also assessed the proportion of urgent admissions among these myelosuppression hospitalizations. We used multivariable logistic regression to examine the association between sociodemographic and hospital-level factors and the risk of myelosuppression hospitalizations. Results: We found significantly higher odds of being hospitalized for the myelosuppression among the Non-Hispanic blacks (aOR=1.3; 95% CI [1.2-1.4]), Hispanics (aOR=1.6; 95% CI [1.4-1.7]), and Asian/Pacific Islanders (aOR=2.3; 95% CI [1.9-2.8]) compared to the Non-Hispanic whites. Additionally, among those patients diagnosed with myelosuppression, the Non-Hispanic blacks (aOR=1.7; 95% CI [1.2-2.3]) and Hispanics (aOR=1.6; 95% CI [1.1-2.2]) had significantly higher odds of getting admitted urgently compared to the Non-Hispanic whites. Conclusion: The risk of myelosuppression hospitalizations is greater in minority patients diagnosed with IBD in the U.S. population than in Non-Hispanic whites. Future studies are needed to investigate factors that are driving these racial variations.